These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 24504330

  • 1. Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
    Ringel F, Kaeda J, Schwarz M, Oberender C, Grille P, Dörken B, Marque F, Manley PW, Radimerski T, le Coutre P.
    Acta Haematol; 2014; 132(1):75-86. PubMed ID: 24504330
    [Abstract] [Full Text] [Related]

  • 2. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
    Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.
    J Natl Cancer Inst; 2013 Mar 20; 105(6):405-23. PubMed ID: 23446755
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
    Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.
    Cancer Biol Ther; 2014 Feb 20; 15(2):207-15. PubMed ID: 24100660
    [Abstract] [Full Text] [Related]

  • 4. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
    Oncotarget; 2014 Sep 30; 5(18):8637-50. PubMed ID: 25226617
    [Abstract] [Full Text] [Related]

  • 5. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
    Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.
    J Hematol Oncol; 2014 Apr 28; 7():37. PubMed ID: 24775308
    [Abstract] [Full Text] [Related]

  • 6. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.
    Acta Pharmacol Sin; 2014 Mar 28; 35(3):401-9. PubMed ID: 24487968
    [Abstract] [Full Text] [Related]

  • 7. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
    Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L, Vigneri P.
    Mol Cancer Ther; 2013 Jun 28; 12(6):1085-98. PubMed ID: 23536723
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.
    Blood; 2004 Oct 15; 104(8):2532-9. PubMed ID: 15256422
    [Abstract] [Full Text] [Related]

  • 9. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
    Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V.
    Nat Chem Biol; 2012 Jan 29; 8(3):285-93. PubMed ID: 22286129
    [Abstract] [Full Text] [Related]

  • 10. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB.
    Cancer Res; 2006 Jul 01; 66(13):6468-72. PubMed ID: 16818614
    [Abstract] [Full Text] [Related]

  • 11. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
    Gu JJ, Santiago L, Mitchell BS.
    Blood; 2005 Apr 15; 105(8):3270-7. PubMed ID: 15604220
    [Abstract] [Full Text] [Related]

  • 12. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T, Cao J, Zou F, Li X, Wang A, Wang W, Liang H, Liu Q, Hu C, Chen C, Hu Z, Wang W, Li L, Ge J, Shen Y, Ren T, Liu J, Xia R, Liu Q.
    Eur J Pharmacol; 2021 Apr 15; 897():173944. PubMed ID: 33581133
    [Abstract] [Full Text] [Related]

  • 13. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.
    Tauchi T, Okabe S, Ashihara E, Kimura S, Maekawa T, Ohyashiki K.
    Oncogene; 2011 Jun 16; 30(24):2789-97. PubMed ID: 21278787
    [Abstract] [Full Text] [Related]

  • 14. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
    Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, Brueggen J, Chène P, Drueckes P, Erdmann D, Furet P, Gerspacher M, Lang M, Ledieu D, Nolan L, Ruetz S, Trappe J, Vangrevelinghe E, Wartmann M, Wyder L, Hofmann F, Radimerski T.
    Mol Cancer Ther; 2010 Jul 16; 9(7):1945-55. PubMed ID: 20587663
    [Abstract] [Full Text] [Related]

  • 15. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
    Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T.
    Int J Cancer; 2008 Jun 01; 122(11):2621-7. PubMed ID: 18338755
    [Abstract] [Full Text] [Related]

  • 16. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
    Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, Chen WY.
    Carcinogenesis; 2012 Feb 01; 33(2):285-93. PubMed ID: 22116466
    [Abstract] [Full Text] [Related]

  • 17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 18. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
    Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, Kreipe HH.
    Blood; 2007 May 01; 109(9):4106-7. PubMed ID: 17449802
    [No Abstract] [Full Text] [Related]

  • 19. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
    Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG.
    J Hematol Oncol; 2011 Feb 07; 4():6. PubMed ID: 21299849
    [Abstract] [Full Text] [Related]

  • 20. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 07; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.